Media Release

M PHARMACEUTICAL INC. CLOSES ACQUISITION OF FDA CLEARED INNOVATIVE INFERTILITY TREATMENT - A NATURAL CONCEPTION LUBRICANT

VANCOUVER, B.C., CANADA (November 8, 2016) - **M Pharmaceutical Inc.** (CSE:MQ, OTCQB: MPHMF, FWB:T3F2), (the "Company" or "M Pharma"), is announcing that the Company has closed its previously announced agreement to acquire from ToConceive LLC., an arms-length private pharmaceutical company, the rights to an FDA approved women's health product, used as a natural conception lubricant as an infertility treatment. The Company issued 20 million shares and will pay a 5% royalty on sales.

"In 2010 the Nobel Prize in Medicine for In Vitro Fertilization emphasized the importance of Sperm Capacitation -*the process when a women's natural conception lubrication, transudate, dissolves the immobilizing cholesterol from the sperm and creates an enzyme to allow the sperm to fertilize the ovum* - for successful conception. This essential capacitation step is inadequate or missing in many couples due to the women's limited production of transudate," noted Mr. Gary Thompson, CEO of M Pharma USA.

"This acquisition is our entry into the women's health market to complement our existing obesity portfolio and has a 510K FDA clearance, is protected by four USPTO patents, and is clinically proven to increase a women's production of transudate. This increase in transudate results in significantly higher success rates for couples trying to conceive without the added expense, or stress, associated with assisted reproduction treatments," added Mr. Thompson.

About M Pharmaceutical Inc.
Formed in early 2015, **M Pharmaceutical Inc.** is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of **C-103,** a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its **Trimeo** capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

For more information contact:
Investor Relations
Phone: +1 604 428 0511
info@m-pharma.ca
www.m-pharma.ca

company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.